Syros Pharmaceuticals (SYRS) was Initiated by Wedbush to “Outperform” and the brokerage firm has set the Price Target at $18. Wedbush advised their investors in a research report released on Jul 25, 2016.
Many Wall Street Analysts have commented on Syros Pharmaceuticals. Syros Pharmaceuticals was Initiated by JMP Securities to “Mkt Outperform” on Jul 25, 2016. Syros Pharmaceuticals was Initiated by Piper Jaffray to “Overweight” on Jul 25, 2016. H.C. Wainwright Initiated Syros Pharmaceuticals on Jul 18, 2016 to “Neutral”, Price Target of the shares are set at $10.